We performed proliferation/viability and CD11b response assays in three MLL-r cell lines (MOLM13, MV4;11, and THP1), three MLL-WT cell lines (U937, HL60, and the chronic myeloid leukemia line (CML) K562), and one NPM1c cell line (Oci-AML3). This evidence concerns the gene KMT2A and chronic myelogenous leukemia, BCR-ABL1 positive.